Berger MS - Search Results

1

Biomarkers to predict response to epidermal growth factor receptor inhibitors.

Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS, Stokoe D. Haas-Kogan DA, et al. Among authors: berger ms. Cell Cycle. 2005 Oct;4(10):1369-72. doi: 10.4161/cc.4.10.2105. Epub 2005 Oct 17. Cell Cycle. 2005. PMID: 16177570

2

Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.

Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O'Neill BP, Jenkins RB, Aldape KD. Burton EC, et al. Clin Cancer Res. 2002 Jan;8(1):180-7. Clin Cancer Res. 2002. PMID: 11801556

3

Proteases and the biology of glioma invasion.

Binder DK, Berger MS. Binder DK, et al. Among authors: berger ms. J Neurooncol. 2002 Jan;56(2):149-58. doi: 10.1023/a:1014566604005. J Neurooncol. 2002. PMID: 11995816 Review.

4

Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.

Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR, Nicholas MK, Stokoe D, Haas-Kogan DA. Ermoian RP, et al. Among authors: berger ms. Clin Cancer Res. 2002 May;8(5):1100-6. Clin Cancer Res. 2002. PMID: 12006525

5

Clinical trial participation among patients enrolled in the Glioma Outcomes Project.

Chang SM, Barker FG 2nd, Schmidt MH, Sloan AE, Kasper R, Phillips L, Shih K, Hariharan S, Berger MS. Chang SM, et al. Among authors: berger ms. Cancer. 2002 May 15;94(10):2681-7. doi: 10.1002/cncr.10536. Cancer. 2002. PMID: 12173337

6

Familial medulloblastoma: case report of one family and review of the literature.

von Koch CS, Gulati M, Aldape K, Berger MS. von Koch CS, et al. Among authors: berger ms. Neurosurgery. 2002 Jul;51(1):227-33; discussion 233. doi: 10.1097/00006123-200207000-00035. Neurosurgery. 2002. PMID: 12182422 Review.

7

Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis.

Sonoda Y, Kanamori M, Deen DF, Cheng SY, Berger MS, Pieper RO. Sonoda Y, et al. Among authors: berger ms. Cancer Res. 2003 Apr 15;63(8):1962-8. Cancer Res. 2003. PMID: 12702589

8

Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors.

Bodell WJ, Gaikwad NW, Miller D, Berger MS. Bodell WJ, et al. Among authors: berger ms. Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):545-51. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12815001

9

A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report.

Chang SM, Kuhn JG, Ian Robins H, Clifford Schold S, Spence AM, Berger MS, Mehta MP, Pollack I, Gilbert M, Prados MD. Chang SM, et al. Among authors: berger ms. Invest New Drugs. 2003 Nov;21(4):429-33. doi: 10.1023/a:1026299118067. Invest New Drugs. 2003. PMID: 14586210

10

Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial.

Prados MD, McDermott M, Chang SM, Wilson CB, Fick J, Culver KW, Van Gilder J, Keles GE, Spence A, Berger M. Prados MD, et al. J Neurooncol. 2003 Dec;65(3):269-78. doi: 10.1023/b:neon.0000003588.18644.9c. J Neurooncol. 2003. PMID: 14682377 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results